Portage, Michigan, March 25, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2025 Annual Meeting of Shareholders is scheduled as follows:
Thursday, May 8, 2025 – 9:30 a.m. Eastern Time
The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at www.investorevents.stryker.com. To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Corporation Annual Meeting" when greeted by the operator.
A recording of the annual meeting will also be available from 10:30 a.m., Eastern Time, on Friday, May 9, 2025 at www.virtualshareholdermeeting.com/SYK2025 until the definitive proxy statement for our 2026 Annual Meeting of Shareholders is filed with the United States Securities and Exchange Commission.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$394.22 |
Daily Change: | 9.39 2.44 |
Daily Volume: | 868,660 |
Market Cap: | US$150.710B |
July 31, 2025 May 01, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load